All filters
Slidesets
Study Design and endpoints in Omics-based biomarker studies | Stephen Williams, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Lipid and Bile acids as NAFLD-related biomarkers | Puneet Puri, MBBS, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Potential approach to identify the NAFLD patient who will develop HCC | Yujin Hoshida, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Simple laboratory based indices | Ray Kim, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Biomarker development in pediatric NAFLD: special challenges in a special population | Saul Karpen, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Dynamic measurement of physiologic functions: any role in NASH diagnostics | Stephen Previs, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Microbiome: diagnostic considerations | Patrick Gillevet
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Management of DAA Failures - Gregory T. Everson, MD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
Who Should We Treat? What is the “Point-of-No-Return”? - Norah Terrault, MD, MPH, FAASLD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
Treatment Experienced GT3 patient with Cirrhosis - Geoffrey McCaughan, MD, PhD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
Is Treatment Cost-effective? - Kosh Agarwal, MD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
What Are the Treatment Options? - Xavier Forns, MD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
When to Treat HCV in a Waiting List Patient? - Stefano Fagiuoli, MD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
Achieving SVR in CTP C – MELD Purgatory - Christophe Duvoux, MD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
What Are the Treatment Options? - Maria Londoño, MD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
Use of HCV+ Donor Grafts - Didier Samuel, MD, PhD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
Post-LT Renal Failure and HCV Rx - Peter Ferenci, MD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
Obstacles to Treatment: Renal Disease, Ribavirin, DDIs - Michael Charlton, MD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
Aging Patients_Immune Activation in Elderly People Living with HIV - Peter Hunt
Presented at:
2022 亚太地区艾滋病和合并感染大会 (APACC)
Slidesets
Neuro Cognitive Complications of Aging - The Social Perspective - Andrew Tan Tze Tho
Presented at:
2022 亚太地区艾滋病和合并感染大会 (APACC)
Slidesets
Differentiated & Simplified PrEP for HIV Prevention - Heather-Marie Schmidt
Presented at:
2022 亚太地区艾滋病和合并感染大会 (APACC)
Slidesets
New Antiretroviral Drugs-Formulations for the Treatment of PLWH and for Prevention of HIV - Jennifer Hoy
Presented at:
2022 亚太地区艾滋病和合并感染大会 (APACC)